louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03288012: Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Official title: Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Alloimmunization
Sickle Cell Disease
Lead sponsor: Sanquin Research & Blood Bank Divisions
Sponsor class: OTHER
Collaborators: name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
name: Radboud University Medical Center
name: HagaZiekenhuis
name: Erasmus Medical Center
First posted: 2017-09-19
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Sickle cell disease population receiving care in the participating hospitals

Brief summary: The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.

Detailed description: The main objectives of this study are to study the role of the innate and adaptive immune response in allo-antibody formation and furthermore to identify the genetic and time dependent clinical risk factors on alloimmunization in SCD patients.

Subjects without allo-antibodies, receiving a red blood cell transfusion, will be included in this study. At 5 time points blood will be drawn from these subjects. (T0: Before transfusion, T1: 1 day after transfusion, T2: 1 week after transfusion, T3: 4 weeks after transfusion, T4: 6 months after transfusion).

At each time point specific markers of the immune system will be measured.

Eligibility criteria: Inclusion Criteria:

* Sickle cell disease
* Receiving a red blood cell transfusion

Exclusion Criteria:

* Previous positive screen for allo-antibodies
* \>25 red blood cell units in the past

Primary outcomes:
measure: The innate and adaptive immune response of patients with sickle cell disease that form allo-antibodies following erythrocyte transfusion, compared to patients that do not form alloantibodies following erythrocyte transfusion
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amsterdam-Zuidoost
country: Netherlands
facility: Academic Medical Center Amsterdam
city: Den Haag
country: Netherlands
facility: HagaZiekenhuis
city: Nijmegen
country: Netherlands
facility: Radboudumc
city: Rotterdam
country: Netherlands
facility: Erasmus MC
Study officials:
References:
Clinical trial NCT05689112: Microscopy Imaging of Whole-mount Stained Human Tissues
Official title: Microscopy Imaging of Whole-mount Stained Human Tissues: Development of an Imaging Platform for Intraoperative Tumor Margin Delineation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Tumor, Brain
Tumor, Breast
Tumor Skin
Keywords: intraoperative assessment
whole-mount H&E staining
surgical border assessment
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 250
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anticpated the study population of tumor assessment:

1. Skin cancer : 50.
2. Brain tumor : 50.
3. Breast cancer : 100.

Brief summary: The goal of this clinical trial is to develop an imaging platform for intraoperative tumor margin delineation in 250 cases of tumor-suffered patients. The main questions it aims to answer are:

• to develop the protocol of rapid assessment of surgical specimens without need for fixation, embedding, and cryosectioning required for conventional histopathology.

Participants will provide a small piece of their surgical specimens from tumor removal surgery .

If there is a comparison group: Researchers will compare normal specimens to see if we can observe the difference.


Eligibility criteria: Inclusion Criteria:

1. Patients who are more than 20 years old.
2. Diagnosed as patients suffered by skin tumor, brain tumor and breast tumor.

Exclusion Criteria:

1. Patients who can't speak and communicate with others.
2. Patients who can't make eventual and exact pathological assessment for his/her diseases.
3. Patients who only can fit for slicing tumor.
4. Removed tissues which obviously vary after severe ray radiation under microscopy observation.
5. Diameter of tumors are under 1 centimeter.
6. Breast carcinoma in situ.

Primary outcomes:
measure: The assessment between tumor cases and control cases
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Dermatology, National Taiwan University Hospital and College of Medicine, National Taiwan University
Study officials:
References:
Clinical trial NCT03099512: The Foot Exercises in Patellofemoral Pain
Official title: The Effects of Foot Exercises on Pain, Biomechanical Characteristics and Functionality of Lower Extremity in Patients With Patellofemoral Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patellofemoral Pain Syndrome
Anterior Knee Pain Syndrome
Pronation Deformity of the Foot
Exercise
Pain
Biomechanics
Functionality
Keywords: Patellofemoral pain
foot deformity
foot pronation
short foot exercise
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2017-04-04
Enrollment: 30
Sex: ALL
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the additional effects of Short Foot Exercises on pain, biomechanical characteristics and functionality of lower extremity in patients with patellofemoral pain.


Eligibility criteria: Inclusion Criteria:

* aged between 25-60
* diagnosed as patellofemoral pain syndrome

Exclusion Criteria:

* Pregnancy
* Having walking disability
* Having a trauma, knee surgery or other arthritis

Primary outcomes:
measure: Visual Analogue Scale
timeFrame: Change from baseline pain at 6th week
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Pınar Kısacık
Study officials:
affiliation: Hacettepe University
name: Pınar Kısacık
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02037646: Quantitative Versus Qualitative Fecal Immunochemical Tests (FIT) to Prioritize Urgency of Colonoscopy Referral
Official title: Evaluating the Effectiveness of Screening Strategies Using Quantitative Versus Qualitative Fecal Immunochemical Test (FIT) to Prioritize Urgency of Colonoscopy Referral - a Randomized Controlled Trial Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Keywords: Colorectal cancer
Screening
Fecal occult blood
Fecal immunochemical test
Qualitative
Quantitative
Lead sponsor: University of Malaya
Sponsor class: OTHER
First posted: 2014-01-16
Enrollment: 700
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The main aim of this study is to determine whether there is a difference in time to diagnosis of advanced colorectal neoplasms using quantitative Fecal Immunochemical Tests (FIT) to prioritize referral for colonoscopy (intervention) compared to usual care (qualitative FIT and appointment-based referral).

Detailed description: It is hypothesized that quantitative FIT will enable faster detection of advanced neoplasms compared to qualitative FIT.

Eligibility criteria: Inclusion Criteria:

* Adults aged 50 years and above

Exclusion Criteria:

* Lower gastrointestinal tract symptoms such as diarrhoea, constipation, per rectal bleeding
* Personal history of colorectal tumour or cancer
* Family history of familial adenomatous polyposis or hereditary non-polyposis colorectal cancer

Primary outcomes:
measure: Time to diagnosis of advanced colorectal neoplasms
timeFrame: 40-90 days from the time of enrolment
Secondary outcomes:
measure: Analysis of screening costs
timeFrame: Up to 90 days following enrolment
measure: Patient anxiety levels
timeFrame: Up to 90 days after enrolment
Other outcomes:
Locations:
city: Kuala Lumpur
country: Malaysia
facility: University of Malaya Medical Centre
Study officials:
affiliation: University of Malaya Medical Centre
name: April C Roslani, MBBCh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03484546: Optimum Menstrual Cycle Time for Endometrioma Excision
Official title: Optimum Menstrual Cycle Time for Endometrioma Excision
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometriosis
Endometrioma
Keywords: ovarian reserve
endometriosis
endometrioma
Lead sponsor: Acibadem University
Sponsor class: OTHER
First posted: 2018-04-02
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women who admitted to out-patient clinic between the ages of 18-40 years,had 4-10cm ovarian unilateral endometrioma and had an indication of laparoscopic ovarian endometrioma excision.

Brief summary: This study evaluates the optimum day of menstrual period for the excision of endometriomas to minimize the damage of surgery to normal ovarian tissue. Patients will be grouped as follicular, ovulatory and luteal according to menstrual days. Ovarian damage will be evaluated with both pathologic examination and anti-mullerian hormone levels before and after the surgery.

Detailed description: Endometriosis is a common gynecologic disease seen in about 10% of women in reproductive age. The most common site of endometriosis is overt. Cystic formation of ovarian endometriosis is called endometrioma (chocolate cyst). Definitive treatment of endometriomas is excision by laparoscopy. The disadvantage of this surgery is the removal of some of the normal ovarian follicles within cystectomy material. This procedure can damage the ovarian reserves with the treatment of endometriomas, which are already the cause of infertility, and lead to the conditions such as infertility or early menopause. It has been understood that the ovarian reserves of the patients who underwent endometrioma cystectomy with the decrease of the Anti-Mullerian Hormone values, which is an over reserve parameter.

Eligibility criteria: Inclusion Criteria:

* 4 to 10 cm unilateral ovarian endometrioma
* having clinically indication of laparoscopic ovarian endometrioma excision

Exclusion Criteria:

* prior gynecologic surgery
* prior abdominal surgery
* additional operation in the same session
* having the diagnosis of premature ovarian failure or ovarian insufficiency
* having any diagnosis of malignancy
* having diagnosis of a non-gynecologic chronicle disease

Primary outcomes:
measure: Determination of ovarian follicle damage via histological examination
timeFrame: 5 days after the surgery
measure: Change of anti-mullerian hormone level 6 months after surgery
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Acibadem Fulya Hospital
city: Istanbul
country: Turkey
facility: Acibadem MAA University Atakent Hospital
city: Istanbul
country: Turkey
facility: Acibadem MAA University Maslak Hospital
Study officials:
affiliation: Acibadem MAA University Maslak Hospital
name: Ozguc Takmaz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02118246: The Effects of Dry Needling & Kinesio Tape on Anterior Knee Pain
Official title: The Clinical Effects of Dry Needling & Kinesio Tape on Myofascial Trigger Point in the Vastus Lateralis Muscle in Subjects With PFPS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patellofemoral Pain Syndrome
Keywords: Knee pain,Dry Needling, kinesioTape,Trigger point
Lead sponsor: University of Social Welfare and Rehabilitation Science
Sponsor class: OTHER
First posted: 2014-04-21
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 57
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patellofemoral Pain Syndrome(PFPS) is one of the most common health-related complaints in today's societies. Myofascial pain syndrome(MPS) have been attributed as the main cause and primary source of musculoskeletal pain. Trigger point of the vastus lateralis muscle may pull the patella superiorly and laterally, increasing compression of the patellofemoral joint during physical activities, result in PFPS and anterior knee pain. The purpose of this study was to investigate the effects of Dry Needling \& kinesio tape on trigger point of vastus lateralis muscle in PFPS subjects.

Detailed description: Pain intensity, pain pressure threshold and Disability of knee were collected at base line and at the end of treatment sessions.

Eligibility criteria: Inclusion Criteria:

1. Presence of a palpable taut band in muscle.
2. Presence of a hypersensitive tender spot in the taut band.
3. Reproduction of the typical referred pain pattern of the trigger point in response to compression. To detect active trigger point, trigger point pressure tolerance was assessed using a mechanical pressure algometer. The investigator applied continuous pressure with the algometer with an approximate pressure of 2.5 kg/cm2.
4. Spontaneous presence of the typical referred pain pattern and/or patient recognition of the referred pain as familiar.

5- Pain of at least 30 mm on a visual analogue scale (VAS) from 0 mm (no pain) to 100 mm (worst imaginable pain).

Exclusion Criteria:

1. had a history of fracture of knee joint, dislocation of patella
2. previous knee or ankle surgery
3. had a history of neurologic condition
4. having physical therapy within the past month before the study
5. pregnancy
6. taking anticoagulants (e.g. warfarin)
7. local infection

Primary outcomes:
measure: Pain
timeFrame: one year
Secondary outcomes:
measure: pain pressure threshold
timeFrame: one year
Other outcomes:
measure: knee disability
timeFrame: one year
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: University of Social Welfare and Rehabilitation Sciences
state: Islamic Republic of
Study officials:
affiliation: University of Social Welfare and Rehabilitation Science
name: Amir M Arab, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02126046: Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Thalassemia Major
Keywords: Cord Blood Transplant
Haploidentical HSCT
Thalassemia major
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2014-04-29
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Allo-hematopoietic stem cell transplantation(HSCT) is the only way to cure β-thalassemia major at present. To expand donor pool，we developed a haplo-identical HSCT (Hi-HSCT) platform. But in prior Hi-HSCT using high dose post-transplant Cyclophosphamide in patients with leukemia, cytopenia post-transplant often developed, which was considered as a symptom of GVHD. Therefore, the investigators add unrelated umbilical cord blood (UCB) to the Hi-HSCT. It has reported that, as third-party cells, UCB will reduce GVHD.The purpose of this study is to determine whether unrelated UCB following Hi-HSCT can improve outcomes of Hi-HSCT in patients with β-thalassemia major.


Eligibility criteria: Inclusion Criteria:

* β-thalassemia major
* \< 18 year old
* Unrelated umbilical cord blood following Haplo-identical HSCT

Exclusion Criteria:

* ≥ 18 year old
* HLA- matched related donors
* Unrelated donor transplants
* Unrelated umbilical cord blood transplants
* Severe iron overload in heart by T2\*

Primary outcomes:
measure: overall survival（OS）
timeFrame: 12 months
measure: TM-free survival（TFS）
timeFrame: 12 months
measure: Transplant Related Martality (TRM)
timeFrame: 12 months
measure: Primary or Secondary Graft Rejection (GR)
timeFrame: 12 months
Secondary outcomes:
measure: The cumulative incidences of acute graft-versus-host disease（GVHD）
timeFrame: 12 months
measure: The cumulative incidences of chronic graft vesus host disease (cGVHD)
timeFrame: 12 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of paediatrics，Nangfang Hospital, Southern Medical University
state: Guangdong
Study officials:
References:
Clinical trial NCT06769646: SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data
Official title: SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD)
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2025-01-10
Enrollment: 110074
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals from the THIN® France, THIN® Italy, THIN® Spain and THIN® UK databases living with T2D and CKD

Brief summary: This study is being carried out in 4 countries (France, Italy, Spain and the UK) to understand the clinical care pathway of population living with type 2 diabetes who also have evidence of chronic kidney disease.

The primary objective is to describe the population with T2D and CKD in terms of demography, clinical characteristics and medication use by CKD stage.


Eligibility criteria: Inclusion Criteria:

1. Adults (18 years old or older) diagnosed with T2D and treated with an antidiabetic medication before or at index date, set up on 1 January 2021
2. With evidence of Kidney damage before or at index date:

   1. diagnosed with CKD
   2. or with a record of eGFR below 60 ml/min/1.73 m\^2
   3. or with a record of uACR above 30 mg/g
3. Consulting a GP (all countries) or an Endocrinologist (France, Spain, Italy) or a Nephrologist (Spain) of the THIN® network.

Exclusion Criteria:

1. aged less than 18 years old at index date
2. less than 360 days prior index date
3. less than 360 days after index date

Primary outcomes:
measure: Prevalence of various CKD stages among patients with type 2 diabetes in the THIN database
timeFrame: From the registration date to 1 January 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Bangalore
country: India
facility: Novo Nordisk Investigational site
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References:
Clinical trial NCT02855346: PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel
Official title: A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Prevention
Lead sponsor: International Partnership for Microbicides, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institutes of Health (NIH)
First posted: 2016-08-04
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: PK and Safety Study of Vaginal Ring Containing Dapivirine and Levonorgestrel

Detailed description: A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel

Eligibility criteria: Inclusion Criteria:

* Healthy women

Exclusion Criteria:

* HIV infected women

Primary outcomes:
measure: Dapivirine and levonorgestrel concentrations in blood and Vaginal fluid
timeFrame: 14 days
Secondary outcomes:
measure: Grade 2 or higher Genitourinary adverse event and Grade 3 or higher adverse event as defined by DAIDS
timeFrame: 14 days
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama Hospital
state: Alabama
city: Pittsburgh
country: United States
facility: Magee Women's Hospital of UPMC
state: Pennsylvania
Study officials:
References:
Clinical trial NCT05650346: Efficacy of Deep Cervical Training Combined With Mobilization Techniques on Forward Head Posture
Official title: Efficacy of Deep Cervical Training Combined With Mobilization Techniques on Forward Head
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Forward Head Posture
Lead sponsor: Egyptian Chinese University
Sponsor class: OTHER
First posted: 2022-12-14
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the efficacy of adding cervical \& thoracic spinal mobilization techniques to deep cervical training compared to deep cervical training alone on Pain, Neck functional ability, Craniovertebral angle.


Eligibility criteria: Inclusion Criteria:

* The craniovertebral angle is less than 50 degrees.
* Age ranges from 18 to 25 years old.
* Forward head is associated with neck pain.

Exclusion Criteria:

A history of any of the following conditions:

* Previous surgery regarding the spine or shoulders.
* Vertebral fractures regarding the cervical spine or the skull.
* Positive neurological signs or evidence of spinal compression
* headaches prior to the onset of neck pain and without cervical origin
* Inner ear or vestibular Problems
* Whiplash Injuries

Primary outcomes:
measure: Craniovertebral Angle
timeFrame: One Month
measure: Deep Neck Core Strength
timeFrame: One Month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: The Egyptian Chinese University
Study officials:
References: